Navigation Links
MAP Pharmaceuticals Reports 2008 Fourth Quarter and Year End Financial Results
Date:3/2/2009

grams initiated in 2008 for UDB and MAP0004, and increases in personnel related expenses to support these clinical programs, as well as manufacturing and stock-based compensation.

Sales, general and administrative expenses for the fourth quarter and year ended December 31, 2008 were $3.7 million and $13.4 million, respectively, compared to $2.7 million and $9.6 million, respectively, for the same periods in 2007. The increase in sales, general and administrative expenses for the fourth quarter ended December 31, 2008 as compared to the same period in 2007 was primarily related to increases in professional fees, stock-based compensation and personnel related expenses. The increase in sales, general and administrative expenses for the year ended December 31, 2008 as compared to the year ended December 31, 2007 was primarily related to increases in stock-based compensation, personnel related expenses, outside services and professional fees.

MAP Pharmaceuticals had cash, cash equivalents and short-term investments as of December 31, 2008 of $44.7 million, compared to $95.0 million as of December 31, 2007. For the fourth quarter and year ended December 31, 2008, non-cash share-based compensation and depreciation was approximately $1.2 million and $5.2 million, respectively. Subsequent to December 31, 2008, the company received a $40 million upfront payment from AstraZeneca pursuant to the worldwide UDB collaboration signed on December 19, 2008.

2009 Financial Outlook

MAP Pharmaceuticals' cash, cash equivalents and short-term investments as of December 31, 2008 and the upfront payment received from AstraZeneca in February 2009 provide operating capital for at least the next twelve months, and the company currently expects its cash usage for fiscal year 2009 to be less than its cash usage for fiscal year 2008. As previously disclosed, in light of the clinical results released recently with respect to MA
'/>"/>

SOURCE MAP Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine news :

1. Transcept Pharmaceuticals to Present at Two Upcoming Conferences
2. Endo Pharmaceuticals Announces Extension of its Tender Offer for Shares of Indevus Pharmaceuticals
3. Alexza Pharmaceuticals Promotes Peter D. Noymer, PhD to Vice President, Product R&D
4. Alseres Pharmaceuticals, Inc. Announces $200,000 Financing
5. Endo Pharmaceuticals Reports Fourth Quarter and Full-Year Financial Results
6. Endo Pharmaceuticals Returns Product Rights to TRANSDUR(TM)-Sufentanil to DURECT
7. Anadys Pharmaceuticals Reports Fourth Quarter and Year-End 2008 Financial Results and Highlights
8. Arbor Pharmaceuticals Announces the Launch of XYLAREX(TM) - A New Nonantibiotic Product for the Dietary Management of Recurrent Ear Infections in Children
9. Endo Pharmaceuticals Appoints William Montague to Board of Directors
10. Access Pharmaceuticals Closes Acquisition of MacroChem Corp.
11. Savient Pharmaceuticals Reports Fourth Quarter and Year-End 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2014)... as 10 million older Americans suffer from depression, often ... However, new research a project that followed the ... years found that Internet use among the elderly ... 30 percent. , "That,s a very strong effect," said ... information studies and media who led the project. "And ...
(Date:4/17/2014)... 17, 2014 EcoHealth Alliance, a nonprofit organization that ... a comprehensive review today examining the current state of ... review calls for improved global surveillance strategies to combat ... outbreak of Ebola in West Africa that has claimed ... Guinea and Liberia. According to the World Health ...
(Date:4/17/2014)... ribbon representing a disease. A pink ribbon is well known ... think of with lung cancer?, Although white has been identified ... black may be the only one they think fits., A ... smokers between the ages of 51 to 79 years old, ... these patients, the emotional toll it can have and how ...
(Date:4/17/2014)... 2014While 94 per cent of Canadians surveyed said they ... for a specific number of genetic conditions, only 80 ... in screening that would sequence their newborns, genomes.,Most newborns ... their first day or two of life in which ... heels and tested for about five to 54 conditions, ...
(Date:4/16/2014)... the embryo. It begins as a glob of identical cells ... the cells of our lungs, muscles, nerves and all the ... feat of reverse tissue engineering, Stanford University researchers have begun ... to proliferate and transform into all of the specialized cells ...
Breaking Medicine News(10 mins):Health News:Internet use can help ward off depression among elderly 2Health News:Re-emergence of Ebola focuses need for global surveillance strategies 2Health News:Re-emergence of Ebola focuses need for global surveillance strategies 3Health News:Unraveling the 'black ribbon' around lung cancer 2Health News:Researcher looks at public perceptions around newborn testing 2Health News:Researcher looks at public perceptions around newborn testing 3Health News:Stanford scientists develop 'playbook' for reverse engineering tissue 2Health News:Stanford scientists develop 'playbook' for reverse engineering tissue 3
... its spa/gourmet green tea at the Las Vegas IECSC, ... the,International Esthetics, Cosmetics & Spa Conference (IECSC) in Las ... will feature one,product unique for its simplicity: green tea. ... Shinwa, an all-natural, organic,green Japanese karigane tea, at the ...
... - SXC Health Solutions, Corp.,("SXC" or the "Company") ... provider of,technology and pharmacy benefits management services, announces ... awarded a,three-year $35 million Pharmacy Benefits Manager (PBM) ... ("TennCare")., Under terms of the proposed agreement, ...
... 23 , - Special Library Association (SLA) ... Anniversary of SLA and Honor Two,Lifetimes of Achievement, ... John,and Jean Piety on being this year,s recipients ... of the Year Award. Mr.,and Mrs. Piety,s contributions ...
... MONDAY JUNE 23, 2008 , LOW SOCIOECONOMIC STATUS INCREASES ... with low socioeconomic status (SES) have more advanced cancers at ... of dying in the five years following cancer diagnosis, according ... the August 1, 2008 issue of CANCER , a ...
... women are struggling with the health fallout caused by a ... -- Most women don,t need a survey to tell them ... feel too sluggish to make it through the day with ... single moms, empty-nesters or grandmothers, many -- if not most ...
... (formerly,Diagnostic Ultrasound Corp.), the maker of BladderScan(R) bladder ... selection, for the second year in a row, ... in Washington State by Washington CEO Magazine., ... as the 4th "Best Company To Work For" ...
Cached Medicine News:Health News:Health and Beauty Come Full Circle: Chado-En Brings Full Benefit of Japanese Green Tea to Spas 2Health News:SXC Health Solutions announces three-year $35 million PBM contract with the State of Tennessee 2Health News:John & Jean Piety Named SLA Engineering Librarians of the Year 2Health News:Risk of death after cancer diagnosis; shift in stage of breast cancer diagnosis 2Health News:Risk of death after cancer diagnosis; shift in stage of breast cancer diagnosis 3Health News:Risk of death after cancer diagnosis; shift in stage of breast cancer diagnosis 4Health News:Risk of death after cancer diagnosis; shift in stage of breast cancer diagnosis 5Health News:So Much to Do, So Little Sleep 2Health News:So Much to Do, So Little Sleep 3Health News:Verathon Inc., Recognized, Second Year Running, as Outstanding Workplace in Washington State by Washington CEO Magazine 2
(Date:1/15/2014)... MultiCell Technologies, Inc. (OTC Bulletin Board: MCET.OB ... composition of matter, biological targets, mechanism of action, methods ... This patent application describes a novel class ... which interfere with the basic homeostatic cellular processes in ...
(Date:1/15/2014)... 15, 2014  According to Millennium Research Group (MRG), ... the United States and ... will expand moderately through 2022, with embolization particles ... increasing interest in drug-eluting beads (DEBs) and radioembolization ...
(Date:1/15/2014)... LAVAL, Quebec , Jan. 15, 2014  Valeant Pharmaceuticals ... VRX) announced that the applicable waiting period under the ... to the previously announced tender offer by its indirect ... the outstanding shares of common stock of Solta Medical, ...
Breaking Medicine Technology:MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3
... Jan. 27, 2012 Neurodevice firm ... Series B investment round led by ... 2011, and secured non-dilutive funding of ... million Innovation Ohio loan and a ...
... GAITHERSBURG, Md., Jan. 27, 2012 GenVec, Inc. (Nasdaq: ... proprietary technologies to create superior therapeutics and vaccines, today ... License Agreement with Novartis (NYSE: NVS).  Under the extension, ... to support its hearing loss and balance disorders program. ...
Cached Medicine Technology:Neurodevice Firm Checkpoint Surgical Raises $3M 2GenVec Extends Research Collaboration with Global Pharmaceutical Company 2GenVec Extends Research Collaboration with Global Pharmaceutical Company 3
... unique thread design is the ultimate anchor ... to pull out, proven delivery, two sutures ... This provides the orthopedic surgeon a superior ... , ,The TwinFix AB anchor was developed ...
... ConTack Labral Anchor is an L-PLA ... for soft tissue reattachment to bone. ... the bony contour of the glenoid, ... Radial Osteo Compression (ROC) design to ...
... can be used for open or arthroscopic ... a sterile disposable inserter. The unique deployment ... insertion of the anchor into bone. ... allows for the two pre-threaded sutures to ...
... TACIT Threaded Anchor and ... in craniofacial and hand ... secure tissue reattachment and ... The small size facilitates ...
Medicine Products: